Loading...
Browse all stories on DeepNewz
Visit
Genentech Acquires Regor's CDK Inhibitors in Definitive Purchase Agreement for $850 Million
Sep 30, 2024, 08:46 AM
Genentech has announced the acquisition of Regor's portfolio of next-generation CDK inhibitors for $850 million upfront, with potential for additional milestone payments. The definitive purchase agreement aims to enhance Genentech's capabilities in the treatment of breast cancer.
View original story
Markets
No • 50%
Yes • 50%
Genentech financial reports and press releases
Yes • 50%
No • 50%
Genentech press releases and clinical trial registries
No • 50%
Yes • 50%
FDA official announcements and press releases
Breast cancer • 25%
Other cancer types • 25%
Colorectal cancer • 25%
Lung cancer • 25%
Genentech press releases and FDA submissions
Increase by 5-10% • 25%
Decrease or no change • 25%
Increase by more than 10% • 25%
Increase by less than 5% • 25%
Stock market data from sources like Yahoo Finance or Bloomberg
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
Genentech financial reports